**Name of Journal:** *World Journal of Diabetes*

**ESPS Manuscript NO:** 41790

**Manuscript Type:** MINIREVIEWS

**Effects of glucose-lowering agents on cardiorespiratory fitness**

Hamasaki H. Effects of glucose-lowering agents on cardiorespiratory fitness

**Hidetaka Hamasaki,** Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, Kagoshima 890-0046, Japan

**ORCID number:** Hidetaka Hamasaki (0000-0002-0124-597X).

**Author contributions:** Hamasaki H wrote the review.

**Conflict-of-interest statement:** No conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author to: Hidetaka Hamasaki, MD, PhD, Doctor,** Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, 2-21-4 Nishida, Kagoshima 8900046, Japan. hhamasaki78@gmail.com

**Telephone:** +81-99-2503535

**Fax:** +81-99-2501470

**Received:** August 27, 2018

**Peer-review started:** August 27, 2018

**First decision:** October 5, 2018

**Revised:** October 15, 2018

**Accepted:** November 26, 2018

**Article in press:**

**Published online:**

**Abstract**

Exercise therapy is essential for the management of type 2 diabetes (T2D). However, patients with T2D show lower physical activity and reduced cardiorespiratory fitness than healthy individuals. It would be ideal for clinicians to co-prescribe glucose-lowering agents that improve cardiorespiratory fitness or exercise capacity in conjunction with exercise therapy. Metformin does not improve cardiorespiratory fitness and may attenuate any beneficial effect of exercise in patients with T2D. In contrast, thiazolidinediones appear to improve cardiorespiratory fitness in patients with T2D. Although evidence is limited, sodium–glucose cotransporter 2 (SGLT2) inhibitors may improve cardiorespiratory fitness in patients with heart failure, and the effect of glucagon-like peptide-1 (GLP-1) receptor agonists on cardiorespiratory fitness is controversial. Recent clinical trials have shown that both SGLT2 inhibitors and GLP-1 receptor agonists exert a favorable effect on cardiovascular disease. It becomes more important to choose drugs that have beneficial effects on the cardiovascular system beyond glucose-lowering effects. Further studies are warranted to determine an ideal glucose-lowering agent combined with exercise therapy for the treatment of T2D.

**Key words**:Type 2 diabetes; Cardiorespiratory fitness; Exercise capacity; Metformin; Thiazolidinedione; Sodium-glucose cotransporter 2 inhibitors; Glucagon-like peptide l receptor agonist

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** What is the most effective combination of drugs and exercise for the treatment of type 2 diabetes? It has become increasingly important for clinicians to prescribe drugs that reduce cardiovascular disease and mortality in addition to their glucose-lowering effects. This review summarized the current literature investigating the effect of glucose-lowering agents on cardiorespiratory fitness. Thiazolidinediones, sodium–glucose cotransporter 2 inhibitors, and glucagon-like peptide-l receptor agonists have the potential to improve cardiorespiratory fitness; however, further research will be needed to confirm.

Hamasaki H. Effects of glucose-lowering agents on cardiorespiratory fitness. *World J Diabetes* 2018; In press

**INTRODUCTION**

More than 400 million people worldwide suffer from diabetes. Diabetes can lead to microvascular and macrovascular complications and increase the physical and psychological burden in patients[1]. Nutrition and exercise therapy are essential for the management of diabetes, and patients with type 1 and 2 diabetes are recommended to engage in regular moderate-to-vigorous intensity aerobic exercise and resistance training[2]. In addition, higher levels of physical activity are associated with reduced risk of breast cancer (14%), colon cancer (21%), ischemic heart disease (25%), and stroke (26%)[3]. Exercise is a standard component of chronic disease prevention and management[4]. However, patients with diabetes typically exhibit lower energy expenditure, physical activity duration[5], skeletal muscle mass[6], and cardiorespiratory fitness[7], and it can be challenging to effectively and safely incorporate exercise therapy in diabetes patients also presenting with vascular complications and comorbidities. Combined diet and exercise therapy is effective against diabetes; however, in more severe cases, drugs are usually required to intensively improve glycemic control. There are currently nine different groups of glucose-lowering agents available: metformin, thiazolidinediones, sulfonylureas, glinides, α-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-l (GLP-1) receptor agonists, and insulin. Of these, metformin[8], SGLT2 inhibitors[9,10], and a GLP-1 receptor agonists[11] have beneficial effects on cardiovascular disease (CVD) as well as glycemic control, making these the drugs of choice for of type 2 diabetes (T2D) treatment[12].

Exercise is important in the primary and secondary prevention of CVD[13] and, thus, should be an integral part of the strategy to reduce CVD risk. Individuals with low cardiorespiratory fitness (< 7.9 metabolic equivalent; MET) have a 1.70-fold and 1.56-fold increased risk of all-cause mortality and cardiovascular events, respectively, compared with those with high cardiorespiratory fitness (≥ 10.8 MET)[14]. Ideally, clinicians should preferably prescribe drugs that improve cardiorespiratory fitness. However, the optimal combination of exercise and glucose-lowering agents remains unclear as the effects of glucose-lowering agents on exercise capacity/cardiorespiratory fitness are not well understood.

This review summarizes the current literature regarding the effects of glucose-lowering agents on cardiorespiratory fitness in humans and aims to highlight the optimum drug selection in the treatment of patients with diabetes who engage in regular exercise.

**METFORMIN AND CARDIORESPIRATORY FITNESS**

Metformin is the most widely used oral glucose-lowering drug with known beneficial effects on macrovascular complications in T2D[15]. While the mechanisms of action of metformin remain unclear, it is known to activate the cellular energy sensor, AMP-activated protein kinase (AMPK), suppress proinflammatory cytokine secretion, inhibit hepatic gluconeogenesis and lipogenesis, and stimulate GLP-1 secretion by modulating the gut microbiota[16]. Metformin is a complex drug with multiple mechanisms of action. While it is the first-line medication recommended by the American Diabetes Association and the European Association of the Study of Diabetes[17], clinicians usually also co-prescribe metformin with exercise therapy. It is important to understand whether metformin affects cardiorespiratory fitness/exercise capacity, and the interaction between metformin and exercise has been well studied[18-25].

Johnson *et al*[18] examined the acute effects of metformin on maximal oxygen consumption (VO2max) during exercise. A cycle ergometer was used for graded maximal exercise tests. Participants cycled at 75–80 rpm with a resistance of 2.0 kp, which was increased by 0.5 kp every 3 min until volitional exhaustion. A single dose (1000 mg) of metformin increased mean VO2 (2.9 ± 0.5 L/min *vs* 2.8 ± 0.5 L/min) during exercise but not VO2max (4.00 ± 0.58 L/min *vs* 4.00 ± 0.66 L/min). Braun *et al*[19] investigated the effect of metformin on aerobic capacity in healthy individuals. Peak aerobic capacity (VO2peak) was measured 7–9 d after administration of either metformin or placebo. An incremental exercise test began using a cycle ergometer at 50–150 W or a treadmill at 6.4–9.6 km/h. The cycle resistance (+25–50 W) and treadmill grade (+2%) were increased every 2 min until exhaustion. The initial dose of metformin was 500 mg/d, which was increased every second day to a maximum of 2000 mg/d. Metformin treatment reduced VO2peak (3.53 ± 0.29 L/min *vs* 3.63 ± 0.9 L/min for metformin and placebo, respectively; −2.7%), and there was no significant association between the decrease in VO2peak and baseline cardiorespiratory fitness. Although the effect was physiologically subtle, short-term treatment with metformin had a negative effect on cardiorespiratory fitness. The same authors also examined the effect of metformin on fat oxidation during and after exercise[20]. Fat oxidation, which was calculated from respiratory gas composition (volume of oxygen consumption (VO2) and volume of carbon dioxide production (VCO2), was higher with metformin compared with placebo treatment during exercise but lower during recovery. In contrast, metformin increased carbohydrate oxidation after exercise. Oxygen consumption was not different at rest or during exercise with metformin. Therefore, metformin may increase the rate of fat oxidation during exercise *via* activation of AMPK, but appears to have no effect on cardiorespiratory fitness. Learsi *et al*[21] examined the effect of metformin on high-intensity, short-duration exercise on anaerobic capacity. Exercise tests comprised a maximal incremental test to evaluate VO2 max, six workload tests with submaximal intensities (40%–90% of maximal power output), and two supramaximal intensity tests (110% of maximal power output). Participants took low-dose metformin (500 mg) or placebo prior to the supramaximal test. Time to exhaustion was improved with metformin (191 ± 33 s *vs* 167 ± 32 s for metformin and placebo, respectively), but VO2 during the supramaximal test was not different between the groups. Maximum O2 deficit and lactate concentrations did not differ between the groups. The authors concluded that metformin improves exercise performance by mediating the alactic anaerobic system. Table 1 summarizes the effects of metformin on cardiorespiratory fitness in healthy individuals. However, what is known about the interaction between metformin and cardiorespiratory fitness in patients with T2D or insulin resistance? A noteworthy study by Boulé *et al*[22] investigated the interaction between metformin and exercise on the hormonal response to a standardized meal. The authors studied 10 patients with mild T2D who took metformin or placebo for 28 d, and measured exercise capacity, glucose, lactate, non-esterified fatty acids, insulin, and glucagon levels on the last two days. Resistance and aerobic exercise tests were conducted using an isokinetic dynamometer and treadmill. After performing resistance exercise (leg extensions and flexions), the patients started three bouts of aerobic exercise comprising walking at 3.5 km/h with 0% gradient for 15 min, then increasing the speed and gradient until just below the ventilatory threshold, followed by walking at an intensity above the ventilator threshold for 5 min. The mean respiratory exchange ratio (0.96 ± 0.02 *vs* 0.98 ± 0.02) was lower, and the mean heart rate (124 ± 9 *vs* 118 ± 8 beats per min) was higher in the metformin group. Mean VO2 was not affected. As expected, metformin improved glycemic response but glycemic response was attenuated in combination with exercise. In addition, glucagon levels were highest in the metformin plus exercise group. It is surprising that exercise has an opposing effect on the glucose-lowering effect of metformin. High-intensity exercise increases insulin counterregulatory hormones, such as epinephrine, norepinephrine, cortisol, and growth hormone, as well as glucagon, which may further deteriorate glucose response in T2D. Boulé *et al*[23] also investigated the long-term effects of metformin on glycemic control and physical fitness in participants in the Diabetes Aerobic and Resistance Exercise trial[26]. Subjects were randomly assigned to four groups, namely, aerobic exercise, resistance training, combined aerobic exercise and resistance training, and control. The exercise group performed progressive aerobic exercise, increasing to an intensity of 75% of maximum heart rate for 45 min. Resistance training included seven exercises: abdominal crunches, seated row, seated biceps curls, supine bench presses, leg presses, shoulder presses, and leg extensions. VO2peak increased in the aerobic group by 0.16 L/min and in the combined exercise group by 0.11 L/min without metformin. However, VO2peak did not change in any of the metformin groups. In the aerobic exercise group, HbA1c levels were reduced with metformin. In the combined exercise group, fasting glucose levels decreased with metformin. There were no significant differences in changes in HbA1c and glucose levels with or without metformin. The study concluded that metformin did not impair physical fitness or glycemic control when combined with exercise. The findings of this study are inconsistent with previous short-term studies that have shown that the addition of exercise to metformin showed a negative effect on cardiorespiratory fitness and glycemia. The authors speculated that difference in the characteristics of the study participants, such as duration of metformin treatment and glycemic control at baseline, may explain this discrepancy.

Two clinical studies have investigated metformin and cardiorespiratory fitness in individuals with insulin resistance and metabolic syndrome. Cadeddu *et al*[24] investigated the effect of metformin, exercise alone, or a combination of metformin and exercise on exercise capacity. Study participants had impaired glucose tolerance and/or impaired fasting glucose and were allocated to one of the three groups. The exercise program comprised 30–50 min cycle ergometry with an intensity of 60%–80% of heart rate reserve based on the age of the subjects. After a 12-wk intervention, the exercise only group had improved VO2peak, whereas the metformin plus exercise therapy group did not. Moreover, metformin plus exercise therapy did not show an improved aerobic threshold compared with the exercise along group. The combination of metformin and exercise was not superior to exercise alone with regard to cardiorespiratory fitness. A recent study in India showed a negative effect of metformin on exercise capacity in patients with newly diagnosed metabolic syndrome[25]. This study was a simple observational study to evaluate changes in VO2, ventilatory anaerobic threshold, and other indicators of cardiorespiratory fitness in response to metformin treatment for 6 wk, and showed that VO2 max decreased from 1.10 ± 0.44 to 0.9 ± 0.39 L/min and ventilatory anaerobic threshold decreased by 1.5 mL/min per kilogram. However, these studies were non-randomized, non-controlled observational studies, and thus, the study design was suboptimal (Table 2).

Metformin improves energy metabolism in skeletal muscle and has a cardioprotective effect *via* AMPK activation[27]. Metformin also inhibits mitochondrial respiratory-chain complex 1 and decreases ATP production[27], which could potentially reduce oxygen consumption during exercise. In addition, metformin increases lactate concentrations and reduces the lactate threshold during exercise[28]; however, lactate accumulation may have a protective effective on skeletal muscle rather than cause fatigue[29]. Previous studies have suggested that the effect of metformin on cardiorespiratory fitness is clinically subtle. However, treatment with metformin does not appear to have a synergetic effect on cardiorespiratory fitness in combination with exercise therapy.

**THIAZOLIDINEDIONES AND CARDIORESPIRATORY FITNESS**

The mechanism of action of thiazolidinediones is mediated by peroxisome proliferator-activated receptors (PPARs)[30]. Thiazolidinediones exert an insulin-sensitizing effect by promoting fatty acid uptake and modulation of secretion of adipokines, such as interleulin-6, tumor necrosis factor-α, and adiponectin[31]. PPAR-γ overactivation by thiazolidinediones increases body weight *via* fluid retention[30] and stimulatory effect on adipogenesis and adipose tissue accumulation[32]; thus, thiazolidinediones may be associated with increased cardiovascular risk in some patients. However, these drugs appear to improve cardiorespiratory fitness in patients with T2D.

In 2005, a randomized, double-blind, placebo-controlled study reported that rosiglitazone, a thiazolidinedione, improved exercise capacity *via* improvement in endothelial function in patients with T2D[33]. Twenty patients were divided into rosiglitazone (4 mg/d) and placebo groups. After a 4-mo intervention, VO2 max increased from 1902 ± 603 mL/min (19.8 ± 5.3 mL/kg per minute) to 2074 ± 585 mL/min (21.2 ± 5.1 mL/kg per minute) in rosiglitazone-treated patients, but showed no improvement in controls. In addition, the change in VO2 max negatively correlated with changes in fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR) was positively correlated with insulin sensitivity, as measured by hyperinsulinemic–euglycemic clamp. Thiazolidinediones may improve VO2 max *via* multiple mechanisms. First, thiazolidinediones enhance gene transcription that promotes adipocyte differentiation and increases fatty acid transport, synthesis, and storage in the adipose tissue by binding to PPARγ. This reduces ectopic fat accumulation in muscle and liver, and improves both cellular lipotoxicity and insulin sensitivity. Second, thiazolidinediones may also activate AMPK, which leads to increased fat oxidation and PPARγ coactivator 1α expression, regulating mitochondrial biogenesis[34]. Mitochondrial dysfunction in patients with T2D is attenuated by thiazolidinediones[35], which may result in an improvement in cardiorespiratory fitness.

Another randomized controlled study investigating the effect of rosiglitazone on cardiorespiratory fitness in patients with T2D was conducted in Greece[36]. Seventy patients (28 men and 42 women) with T2D were randomly assigned to a rosiglitazone (8 mg/d) treatment group or a control group. Rosiglitazone treatment for 6 mo increased VO2peak from 24.47 ± 3.98 to 26.39 ± 4.04 mL/kg per minute. Changes in adiponectin, HOMA-IR, and HbA1c levels were independent predictors of incremental increase in VO2peak. Rosiglitazone, a PPARγ activator, may improve cardiorespiratory fitness *via* upregulation of adiponectin. Recently, Yokota *et al*[37] showed that pioglitazone improves cardiorespiratory fitness in Japanese patients with metabolic syndrome. Fourteen male patients with metabolic syndrome received 15 mg/d of pioglitazone for four months. Pioglitazone increased VO2peak from 25.1 ± 4.9 to 27.2 ± 3.9 mL/kg per minute, and the anaerobic threshold from 12.7 ± 1.9 to 13.6 ± 0.6 mL/kg per minute. Pioglitazone also decreased the intramyocellular lipid content in resting calf muscle by 26%, with no concurrent change in the cross-sectional area of the muscle. There was an inverse correlation between the increase in anaerobic threshold and the decrease in intramyocellular lipid content. These data suggest that pioglitazone improves cardiorespiratory fitness *via* skeletal muscle fatty acid metabolism. In addition, pioglitazone decreased muscle phosphocreatinine loss during exercise, suggesting that altered mitochondrial function contributes to the improvement in skeletal muscle energy metabolism. Taken together, these studies indicate that thiazolidinediones have a beneficial effect on cardiorespiratory fitness in patients with T2D and metabolic syndrome (Table 3).

**INCRETIN-RELATED DRUGS AND CARDIORESPIRATORY FITNESS**

GLP-1 is secreted by the intestine and has multiple physiological effects, including brain neuroprotection, suppressing appetite, cardiovascular protection, improving cardiac function, slowing gastric emptying, decreasing glucose production in the liver, increasing glucose uptake in adipose tissue and skeletal muscle, stimulating insulin secretion, suppressing glucagon secretion, promoting pancreatic β-cell proliferation, and inhibiting pancreatic β-cell apoptosis[38]. Secretion and function of GLP-1 is severely diminished in patients with T2D, and GLP-1 receptor agonists effectively improve diabetes and obesity *via* pleiotropic effects. Additionally, there could be an interaction between exercise and GLP-1 in patients with T2D[39]. The effect of GLP-1 receptor agonists on exercise capacity/cardiorespiratory fitness remains controversial. Lepore *et al*[40] investigated whether albiglutide, a long-acting GLP-1 receptor agonist, improved cardiac function and exercise performance in patients with chronic heart failure. Eighty-one patients participated in this multicenter, randomized, placebo-controlled study, and received either 30 mg of albiglutide or placebo for 12 wk. The albiglutide group showed improved VO2peak (from 16.2 ± 0.9 to 17.1 ± 1 mL/kg per minute), an increase of 1.5 mL/min per kilogram compared with the placebo group. However, no significant improvement in cardiac function, 6-min walk test, myocardial glucose, and oxygen use was observed. The authors stated that the improvement in cardiorespiratory fitness may have been mediated by a physiological effect rather than cardiac function due to the administration of albiglutide. Scalzo *et al*[41] investigated the effect of exenatide on functional exercise capacity in patients with T2D after 3-mo treatment of 10 μg twice-daily exenatide. Exenatide did not improve VO2peak or endothelial function, but diastolic cardiac function and arterial stiffness improved.

The controversial results from these studies may be attributed to patient characteristics. One study was conducted using patients with chronic heart failure (without diabetes) and the other used patients with mild T2D (without heart failure). Although the underlying mechanisms are unknown, the baseline cardiac function may have influenced the change in cardiorespiratory fitness due to the GLP-1 receptor agonist treatment.

A randomized, placebo-controlled, double-blind, parallel group, phase IV trial which aims at examining the effect of liraglutide on physical performance in patients with T2D is currently underway[42], with promising results.

To the best of our knowledge, to date, no human studies have reported the effect of DPP-4 inhibitors on exercise capacity/cardiorespiratory fitness. However, one animal study suggested that exercise capacity and mitochondrial biogenesis in skeletal muscle are improved by the administration of a DPP-4 inhibitor in mice with heart failure[43]. DPP-4 inhibitors may also have the potential to improve exercise capacity/cardiorespiratory fitness in humans.

**SGLT2 INHIBITORS AND CARDIORESPIRATORY FITNESS**

SGLT2 inhibitors decrease glucose reabsorption at the proximal renal tubules, which increases urinary glucose excretion and improves glycemic control. SGLT2 inhibitors also exert various metabolic effects, including weight loss, insulin sensitivity improvement, blood pressure lowering, renal hemodynamic modulation, and reduction in albuminuria, which leads to cardiovascular and renal protection[44]. Treatment using empaglifrozin resulted in a 35% risk reduction in hospitalization for heart failure compared with placebo[9], suggesting that SGLT2 inhibitors also have an effect on cardiorespiratory fitness in patients with T2D.

To date, two pilot studies have investigated whether empaglifrozin improves cardiorespiratory fitness in patients with T2D with heart failure. Nunez *et al*[45] showed that short-term (4 wk) empaglifrozin treatment increased VO2peak by 1.21 mL/kg per minute (11.1%) from baseline. Conversely, Carbone *et al*[46] showed that empaglifrozin treatment for 4 wk did not significantly improve VO2peak (14.5 mL/kg *vs* 15.8 mL/kg per minute). Intriguingly, patients concomitantly treated with loop diuretics demonstrated improved VO2peak (+0.9 mL/kg per minute), whereas those without loop diuretics demonstrated a decrease in VO2peak (−0.9 mL/kg per minute). Indeed, all patients in the study by Nunenz *et al*[44] received loop diuretics. The authors hypothesized that empaglifrozin acts on the proximal renal tubules by interacting with sodium/hydrogen exchangers, thereby increasing sodium delivery at the distal renal tubules and enhancing the effect of loop diuretics[47,48]. Carbone *et al*[46] also speculated that empaglifrozin improves cardiorespiratory fitness in patients concomitantly treated with loop diuretics by reducing the activity of the rennin–angiotensin–aldosterone system. Empaglifrozin may exert cardiovascular and renal benefits *via* changes in myocardial and renal energy metabolism. Empaglifrozin increases ketone oxidation instead of fat and glucose oxidation, which can improve cardiac and renal work efficiency[49]. Taken together, these studies suggest that SGLT2 inhibitors improve cardiorespiratory fitness in patients with T2D with heart failure (Table 4).

**CONCLUSION**

Metformin does not improve cardiorespiratory fitness and may attenuate a beneficial effect of exercise on cardiorespiratory fitness in patients with T2D. In contrast, thiazolidinediones appear to improve cardiorespiratory fitness in patients with T2D. The effect of GLP-1 receptor agonists on cardiorespiratory fitness remains controversial and is not fully understood. Notably, SGLT2 inhibitors may improve cardiorespiratory fitness in patients with heart failure by modulating cardiac energy metabolism or *via* a synergetic effect with loop diuretics. Unfortunately, no human studies have examined the effect of DPP-4 inhibitors, sulfonylureas, glinides, or α-glucosidase inhibitors on cardiorespiratory fitness (Table 5). This review cannot recommend the optimal combination of exercise and glucose-lowering agents with regard to cardiorespiratory fitness in patients with T2D; however, thiazolidinediones, GLP-1 receptor agonists, and SGLT2 inhibitors have the potential to improve both glycemic control and cardiorespiratory fitness without interfering with exercise therapy. Further studies are warranted to demonstrate the clinical benefits of glucose-lowering agents for cardiorespiratory fitness, and to elucidate the underlying mechanisms of action.

**REFERENCS**

1 **Chatterjee S**, Khunti K, Davies MJ. Type 2 diabetes. *Lancet* 2017; **389**: 2239-2251 [PMID: 28190580 DOI: 10.1016/S0140-6736(17)30058-2]

2 **American Diabetes Association**. 4. Lifestyle Management: Standards of Medical Care in Diabetes-2018. *Diabetes Care* 2018; **41**: S38-S50 [PMID: 29222375 DOI: 10.2337/dc18-S004]

3 **Kyu HH**, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman JL, Delwiche K, Iannarone ML, Moyer ML, Cercy K, Vos T, Murray CJ, Forouzanfar MH. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. *BMJ* 2016; **354**: i3857 [PMID: 27510511 DOI: 10.1136/bmj.i3857]

4 **American College of Sports Medicine**. Exercise is Medicine®: A Global Health Initiative. Available from: URL: http://www.exerciseismedicine.org/

5 **Fagour C**, Gonzalez C, Pezzino S, Florenty S, Rosette-Narece M, Gin H, Rigalleau V. Low physical activity in patients with type 2 diabetes: the role of obesity. *Diabetes Metab* 2013; **39**: 85-87 [PMID: 23159129 DOI: 10.1016/j.diabet.2012.09.003]

6 **Park SW**, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, de Rekeneire N, Harris TB, Kritchevsky S, Tylavsky FA, Nevitt M, Cho YW, Newman AB; Health, Aging, and Body Composition Study. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. *Diabetes Care* 2009; **32**: 1993-1997 [PMID: 19549734 DOI: 10.2337/dc09-0264]

7 **Ozdirenç M**, Biberoğlu S, Ozcan A. Evaluation of physical fitness in patients with Type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2003; **60**: 171-176 [PMID: 12757989 DOI: 10.1016/S0168-8227(03)00064-0]

8 **Anabtawi A**, Miles JM. Metformin: nonglycemic effects and potential novel indications. *Endocr Pract* 2016; **22**: 999-1007 [PMID: 27579542 DOI: 10.4158/EP151145.RA]

9 **Zinman B**, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med* 2015; **373**: 2117-2128 [PMID: 26378978 DOI: 10.1056/NEJMoa1504720]

10 **Neal B**, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med* 2017; **377**: 644-657 [PMID: 28605608 DOI: 10.1056/NEJMoa1611925]

11 **Marso SP**, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 2016; **375**: 311-322 [PMID: 27295427 DOI: 10.1056/NEJMoa1603827]

12 **American Diabetes Association**. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. *Diabetes Care* 2018; **41**: S73-S85 [PMID: 29222379 DOI: 10.2337/dc18-S008]

13 **Alves AJ**, Viana JL, Cavalcante SL, Oliveira NL, Duarte JA, Mota J, Oliveira J, Ribeiro F. Physical activity in primary and secondary prevention of cardiovascular disease: Overview updated. *World J Cardiol* 2016; **8**: 575-583 [PMID: 27847558 DOI: 10.4330/wjc.v8.i10.575]

14 **Kodama S**, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, Sugawara A, Totsuka K, Shimano H, Ohashi Y, Yamada N, Sone H. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. *JAMA* 2009; **301**: 2024-2035 [PMID: 19454641 DOI: 10.1001/jama.2009.681]

15 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; **352**: 854-865 [PMID: 9742977 DOI: 10.1016/S0140-6736(98)07037-8]

16 **Rena G**, Hardie DG, Pearson ER. The mechanisms of action of metformin. *Diabetologia* 2017; **60**: 1577-1585 [PMID: 28776086 DOI: 10.1007/s00125-017-4342-z]

17 **Inzucchi SE**, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2012; **35**: 1364-1379 [PMID: 22517736 DOI: 10.2337/dc12-0413]

18 **Johnson ST**, Robert C, Bell GJ, Bell RC, Lewanczuk RZ, Boulé NG. Acute effect of metformin on exercise capacity in active males. *Diabetes Obes Metab* 2008; **10**: 747-754 [PMID: 17970761 DOI: 10.1111/j.1463-1326.2007.00805.x]

19 **Braun B**, Eze P, Stephens BR, Hagobian TA, Sharoff CG, Chipkin SR, Goldstein B. Impact of metformin on peak aerobic capacity. *Appl Physiol Nutr Metab* 2008; **33**: 61-67 [PMID: 18347654 DOI: 10.1139/H07-144]

20 **Malin SK**, Stephens BR, Sharoff CG, Hagobian TA, Chipkin SR, Braun B. Metformin's effect on exercise and postexercise substrate oxidation. *Int J Sport Nutr Exerc Metab* 2010; **20**: 63-71 [PMID: 20190353 DOI: 10.1123/ijsnem.20.1.63]

21 **Learsi SK**, Bastos-Silva VJ, Lima-Silva AE, Bertuzzi R, De Araujo GG. Metformin improves performance in high-intensity exercise, but not anaerobic capacity in healthy male subjects. *Clin Exp Pharmacol Physiol* 2015; **42**: 1025-1029 [PMID: 26250859 DOI: 10.1111/1440-1681.12474]

22 **Boulé NG**, Robert C, Bell GJ, Johnson ST, Bell RC, Lewanczuk RZ, Gabr RQ, Brocks DR. Metformin and exercise in type 2 diabetes: examining treatment modality interactions. *Diabetes Care* 2011; **34**: 1469-1474 [PMID: 21602430 DOI: 10.2337/dc10-2207]

23 **Boulé NG**, Kenny GP, Larose J, Khandwala F, Kuzik N, Sigal RJ. Does metformin modify the effect on glycaemic control of aerobic exercise, resistance exercise or both? *Diabetologia* 2013; **56**: 2378-2382 [PMID: 23975325 DOI: 10.1007/s00125-013-3026-6]

24 **Sigal RJ**, Kenny GP, Boulé NG, Wells GA, Prud'homme D, Fortier M, Reid RD, Tulloch H, Coyle D, Phillips P, Jennings A, Jaffey J. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. *Ann Intern Med* 2007; **147**: 357-369 [PMID: 17876019 DOI: 10.7326/0003-4819-147-6-200709180-00005]

25 **Cadeddu C**, Nocco S, Cugusi L, Deidda M, Bina A, Fabio O, Bandinu S, Cossu E, Baroni MG, Mercuro G. Effects of metformin and exercise training, alone or in association, on cardio-pulmonary performance and quality of life in insulin resistance patients. *Cardiovasc Diabetol* 2014; **13**: 93 [PMID: 24884495 DOI: 10.1186/1475-2840-13-93]

26 **Paul AA**, Dkhar SA, Kamalanathan S, Thabah MM, George M, Chandrasekaran I, Gunaseelan V, Selvarajan S. Effect of metformin on exercise capacity in metabolic syndrome. *Diabetes Metab Syndr* 2017; **11** Suppl 1: S403-S406 [PMID: 28283393 DOI: 10.1016/j.dsx.2017.03.025]

27 **Foretz M**, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. *Cell Metab* 2014; **20**: 953-966 [PMID: 25456737 DOI: 10.1016/j.cmet.2014.09.018]

28 **DeFronzo R**, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. *Metabolism* 2016; **65**: 20-29 [PMID: 26773926 DOI: 10.1016/j.metabol.2015.10.014]

29 **Lindinger MI**. Combating muscle fatigue: extracellular lactic acidosis and catecholamines. *J Physiol* 2007; **581**: 419 [PMID: 17379626 DOI: 10.1113/jphysiol.2007.132209]

30 **Nanjan MJ**, Mohammed M, Prashantha Kumar BR, Chandrasekar MJN. Thiazolidinediones as antidiabetic agents: A critical review. *Bioorg Chem* 2018; **77**: 548-567 [PMID: 29475164 DOI: 10.1016/j.bioorg.2018.02.009]

31 **Lehrke M**, Lazar MA. The many faces of PPARgamma. *Cell* 2005; **123**: 993-999 [PMID: 16360030 DOI: 10.1016/j.cell.2005.11.026]

32 **Hauner H**. The mode of action of thiazolidinediones. *Diabetes Metab Res Rev* 2002; **18** Suppl 2: S10-S15 [PMID: 11921433 DOI: 10.1002/dmrr.249]

33 **Regensteiner JG**, Bauer TA, Reusch JE. Rosiglitazone improves exercise capacity in individuals with type 2 diabetes. *Diabetes Care* 2005; **28**: 2877-2883 [PMID: 16306548 DOI: 10.2337/diacare.28.12.2877]

34 **LeBrasseur NK**, Ruderman NB. Why might thiazolidinediones increase exercise capacity in patients with type 2 diabetes? *Diabetes Care* 2005; **28**: 2975-2977 [PMID: 16306565 DOI: 10.2337/diacare.28.12.2975]

35 **Colca JR**, McDonald WG, Kletzien RF. Mitochondrial target of thiazolidinediones. *Diabetes Obes Metab* 2014; **16**: 1048-1054 [PMID: 24774061 DOI: 10.1111/dom.12308]

36 **Kadoglou NP**, Iliadis F, Angelopoulou N, Perrea D, Liapis CD, Alevizos M. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus. *Diabet Med* 2008; **25**: 333-340 [PMID: 18307460 DOI: 10.1111/j.1464-5491.2007.02375.x]

37 **Yokota T**, Kinugawa S, Hirabayashi K, Suga T, Takada S, Omokawa M, Kadoguchi T, Takahashi M, Fukushima A, Matsushima S, Yamato M, Okita K, Tsutsui H. Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome. *J Diabetes Investig* 2017; **8**: 535-541 [PMID: 27930876 DOI: 10.1111/jdi.12606]

38 **Gallwitz B**. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents. *Drugs* 2011; **71**: 1675-1688 [PMID: 21902291 DOI: 10.2165/11592810-000000000-00000]

39 **Hamasaki H**. Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment? *World J Diabetes* 2018; **9**: 138-140 [PMID: 30147850 DOI: 10.4239/wjd.v9.i8.138]

40 **Lepore JJ**, Olson E, Demopoulos L, Haws T, Fang Z, Barbour AM, Fossler M, Davila-Roman VG, Russell SD, Gropler RJ. Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. *JACC Heart Fail* 2016; **4**: 559-566 [PMID: 27039125 DOI: 10.1016/j.jchf.2016.01.008]

41 **Scalzo RL**, Moreau KL, Ozemek C, Herlache L, McMillin S, Gilligan S, Huebschmann AG, Bauer TA, Dorosz J, Reusch JE, Regensteiner JG. Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes. *J Diabetes Complications* 2017; **31**: 449-455 [PMID: 27884660 DOI: 10.1016/j.jdiacomp.2016.10.003]

42 **Wägner AM**, Miranda-Calderín G, Ugarte-Lopetegui MA, Marrero-Santiago H, Suárez-Castellano L, Alberiche-Ruano MDP, Castillo-García N, López-Madrazo MJ, Alemán C, Martínez-Mancebo C, López-Ríos L, Díez Del Pino A, Nóvoa-Mogollón FJ. Effect of liraglutide on physical performance in type 2 diabetes (LIPER2): A randomised, double-blind, controlled trial. *Contemp Clin Trials Commun* 2016; **4**: 46-51 [PMID: 29736469 DOI: 10.1016/j.conctc.2016.06.007]

43 **Takada S**, Masaki Y, Kinugawa S, Matsumoto J, Furihata T, Mizushima W, Kadoguchi T, Fukushima A, Homma T, Takahashi M, Harashima S, Matsushima S, Yokota T, Tanaka S, Okita K, Tsutsui H. Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling. *Cardiovasc Res* 2016; **111**: 338-347 [PMID: 27450980 DOI: 10.1093/cvr/cvw182]

44 **Heerspink HJ**, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. *Circulation* 2016; **134**: 752-772 [PMID: 27470878 DOI: 10.1161/CIRCULATIONAHA.116.021887]

45 **Núñez J**, Palau P, Domínguez E, Mollar A, Núñez E, Ramón JM, Miñana G, Santas E, Fácila L, Górriz JL, Sanchis J, Bayés-Genís A. Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study. *Clin Cardiol* 2018; **41**: 476-480 [PMID: 29663436 DOI: 10.1002/clc.22899]

46 **Carbone S**, Canada JM, Billingsley HE, Kadariya D, Dixon DL, Trankle CR, Buckley LF, Markley R, Vo C, Medina de Chazal H, Christopher S, Buzzetti R, Van Tassell BW, Abbate A. Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. *Diabetes Obes Metab* 2018; **20**: 2014-2018 [PMID: 29603546 DOI: 10.1111/dom.13309]

47 **Packer M**, Anker SD, Butler J, Filippatos G, Zannad F. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. *JAMA Cardiol* 2017; **2**: 1025-1029 [PMID: 28768320 DOI: 10.1001/jamacardio.2017.2275]

48 **Perrone-Filardi P**, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni AP, Sesti G, Ferrannini E. Mechanisms linking empagliflozin to cardiovascular and renal protection. *Int J Cardiol* 2017; **241**: 450-456 [PMID: 28395981 DOI: 10.1016/j.ijcard.2017.03.089]

49 **Mudaliar S**, Alloju S, Henry RR. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. *Diabetes Care* 2016; **39**: 1115-1122 [PMID: 27289124 DOI: 10.2337/dc16-0542]

**P-Reviewer:** Beltowski J, Jiang L, Raghow R, Reggiani GM **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Endocrinology and metabolism

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

**Table 1 Effects of metformin on cardiorespiratory fitness in healthy individuals**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Subjects** | **Metformin dose and** **intervention** | **Results** |
| Johnson *et al*[18], 2008 | Randomized, double-blind, placebo-controlled, crossover study | 11 healthy and active men  Age: 29.9 ± 3.7 yr  Sex: All men  BMI: 25.2 ± 2.8 kg/m2 | 1000 mg/d  Cycle ergometer at the mean intensity of 69 ± 5.5% of VO2max | VO2max→, ventilator threshold→, maximal heart rate→, time to fatigue→  Lactate↓, blood glucose concentrations↓ |
| Braun *et al*[19], 2008 | Non-randomized, placebo-controlled study | 18 healthy subjects  Age: 27.9 ± 3.3 yr  Sex: 11 men and 7 women  BMI: 24.1 ± 3.6 kg/ m2 | 2000 mg/d  Treadmill or cycle ergometer | VO2peak↓, peak heart rate↓, peak ventilation↓, peak respiratory exchange ratio↓, exercise duration↓  Rating of perceived exertion→ |
| Malin *et al*[20], 2010 | Non-randomized, double-blind, counterbalanced crossover study | 15 healthy and active subjects  Age: 25 ± 4.4 yr  Sex: 7 men and 8 women  BMI: 22.8 ± 2.7 kg/m2 | 2000 mg/d  Cycle exercise at 5 submaximal cycle workloads | VO2→  During exercise: fat oxidation↑  Postexercise: fat oxidation↓ |
| Learsi *et al*[21], 2015 | Randomized, placebo-controlled, counterbalanced study | 10 healthy men  Age: 23.5 ± 3.6 yr  Sex: all men  BMI: no description (height: 170.4 ± 4.8 cm, weight: 66.4 ± 6.5 kg) | 500 mg/d  Cycle ergometer: an incremental test, 6 submaximal workload test at 40%–90% VO2max, 2 supramaximal tests at 110% VO2max | VO2→, maximal accumulated oxygen deficit→, lactate concentrations→  Time to exhaustion↑, VO2 recovery↑ |

BMI: Body mass index; VO2: Oxygen consumption.

**Table 2 Effects of metformin on cardiorespiratory fitness in patients with type 2 diabetes and metabolic syndrome**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Subjects** | **Metformin dose and** **intervention** | **Results** |
| Boulé*et al*[22], 2011 | Randomized, placebo-controlled, crossover study | 10 patients with type 2 diabetes  Age: 58 ± 6 yr  Sex: 8 men and 2 women  BMI: 28.6 ± 5.3 kg/m2  HbA1c: 6.5 ± 0.6% | 2000 mg/d  Exercise mode: Treadmill at three different submaximal intensities  Study duration: 22 wk | VO2→, respiratory exchange ratio↓  Heart rate↑, lactate↑, rating of perceived exertion↑ |
| Boulé*et al*[23], 2013 | Randomized controlled trial (Diabetes Aerobic and Resistance Exercise) trial | 251 patients with type 2 diabetes (143 patients treated with metformin and 82 patients treated without metformin)  Age: 54.9 ± 7.1 yr *vs* 53.1 ± 6.9 yr  Sex (Men/Women): 100/43 *vs* 46/36  BMI: 33.3 ± 5.5 kg/m2 *vs* 33.3 ± 6.4 kg/m2  HbA1c: 7.78 ± 0.9% *vs* 7.47 ± 0.77% | Approximately 1600 mg/d  Exercise mode: Aerobic training, resistance training, and combined aerobic and resistance training  Study duration: 4 wk | VO2peak→ |
| Cadeddu *et al*[25], 2014 | Non-randomized, non-controlled trial | 75 patients with insulin resistance  Age: 46.2 ± 11 yr  Sex: 35 men and 40 women  BMI: 29.8 ± 4.1 kg/m2 | 1000 mg/d  30–50 min of cycle exercise at the intensity of 60%–80% of the heart rate reserve  Study duration: 12 wk | VO2peak→ |
| Paul *et al*[26], 2017 | Prospective observational study | 15 patients with metabolic syndrome  Age: no description  Sex: no description  BMI: no description (weight: 75.4 ± 12.08 kg) | 1000 mg/d  No intervention  Study duration: 6 wk | VO2max↓ |

BMI: Body mass index; HbA1c: Hemoglobin A1c; VO2: Oxygen consumption.

**Table 3 Effects of thiazolidinediones on cardiorespiratory fitness in patients with type 2 diabetes and metabolic syndrome**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Subjects** | **Thiazolidinedione dose** | **Results** |
| Regensteiner *et al*[33], 2005 | Randomized controlled trial | 20 patients with type 2 diabetes (10 patients received rosiglitazone and 10 patients received a placebo)  Age: 55 ± 7 yr *vs* 56 ± 1 yr  Sex (Men/Women): 5/5 *vs* 5/5  BMI: 32.2 ± 5.6 kg/m2 *vs* 30.4 ± 5.8 kg/m2  HbA1c: 7.2 ± 1.1% *vs* 7.2 ± 1.0% | Rosiglitazone, 4 mg/d | VO2↑, insulin sensitivity↑, endothelial function↑ |
| Kadoglou *et al*[36], 2008 | Randomized controlled trial | 70 patients with type 2 diabetes (35 patients received rosiglitazone and 35 patients received a placebo)  Age: 63.8 ± 7.3 yr *vs* 66.7 ± 9.6 yr  Sex (Men/Women): 14/21 *vs* 16/19  BMI: 29.5 ± 3.8 kg/m2 *vs* 29.9 ± 4.3 kg/m2  HbA1c: 8.2 ± 1.2% *vs* 8 ± 0.8% | Rosiglitazone, 8 mg/d | VO2peak↑, duration of the exercise test↑, oxygen pulse↑  Insulin resistance↓, diastolic blood pressure↓ |
| Yokota *et al*[37], 2017 | Before-after study | 14 patients with metabolic syndrome  Age: 52 ± 11 yr  Sex: All men  BMI: 26.6 ± 3.3 kg/m2  HbA1c: 5.7 ± 0.6% | Pioglitazone, 15 mg/d | VO2peak↑, anaerobic threshold↑  Intramyocellular lipid content↓, muscle phosphocreatinine loss during exercise↓ |

BMI: Body mass index; HbA1c: Hemoglobin A1c; VO2: Oxygen consumption.

**Table 4 Effects of sodium–glucose cotransporter 2 inihibitors on cardiorespiratory fitness in patients with type 2 diabetes**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Subjects** | **SGLT2 inhibitors dose** | **Results** |
| Núñez *et al*[45], 2017 | Before-after study | 19 patients with type 2 diabetes and heart failure  Age (median): 72 yr  Sex: 14 men and 5 women  BMI: 30.6 ± 5.5 kg/m2 HbA1c: No description | Empaglifrozin, 10 mg/d | VO2peak↑, ventilatory efficiency during exercise↑, 6-minute walking distance↑, ↓antigen carbohydrate 125 |
| Carbone *et al*[46], 2018 | Before-after study | 15 patients with type 2 diabetes and heart failure  Age (median): 60 yr  Sex: 7 men and 8 women  BMI (median): 34 kg/m2  HbA1c (median): 7.8% | Empaglifrozin, 10 mg/d | VO2peak↑ in patients using loop diuretics  VO2peak↓ in patients without loop diuretics |

SGLT2: Sodium–glucose cotransporter 2; BMI: Body mass index; HbA1c: Hemoglobin A1c; VO2: Oxygen consumption.

**Table 5 Effect of glucose-lowering agents on cardiorespiratory fitness**

|  |  |
| --- | --- |
| **Glucose-lowering agents** | **Cardiorespiratory fitness** |
| Metformin | → or ↓ |
| Thiazolidinediones | ↑ |
| DPP-4 inhibitors | Unknown  (↑ in mice with heart failure) |
| GLP-1 receptor agonists | ↑ in patients with heart failure  → in patients with type 2 diabetes |
| SGLT2 inhibitors | ↑ in patients treated with loop diuretics |

DPP-4: Dipeptidyl peptidase-4; GLP-1: Glucagon-like peptide-l; SGLT2: Sodium–glucose cotransporter 2.